Adherium Limited Issues Corrected Notice for 20 Million Omitted Shortfall Options from July 2025

Reason Behind Adherium’s Delayed Correction for 20 Million ADRAW Options

Adherium clarified that the 20 million options now disclosed were originally issued on 22 July 2025, almost a year prior to the corrective filing on 30 June 2026. The company stated the Appendix 3G was lodged specifically to "update the 20,000,000 options that were not included in the Appendix 3G lodged on 22 July 2025." The omission appears to have been an administrative oversight rather than a change to the underlying transaction.

Additionally, Adherium noted these securities had been previously announced via an updated Appendix 3B lodged on 1 July 2025, so the market was not entirely unaware of their existence. However, the formal Appendix 3G notification—required for unquoted Equity securities—was incomplete until this recent filing. The company did not disclose the cause of the original omission or whether ASX inquiries prompted the correction.

Role of ADRAW Shortfall Options Within Adherium’s Retail Offer

The 20 million options covered by this correction are described as "Shortfall Options from the Retail Offer." In Australian Capital Markets terminology, shortfall options typically arise when a retail entitlement offer is undersubscribed, and the remaining securities or options are allocated through a bookbuild or shortfall process. These options were issued for no cash consideration, meaning Adherium received no direct payment upon issuance.

The ADRAW options have a low exercise price of $0.005, reflecting Adherium's micro-cap status. If all 325,062,185 ADRAW options outstanding were exercised, the company could raise approximately $1.625 million, though no guidance on expected exercise rates was provided. The options expire on 31 July 2026, making the upcoming weeks critical for any exercise activity.

Adherium’s Comprehensive Unquoted Options Portfolio

The capital table in the update reveals a complex structure with thirteen unquoted option series. The largest by volume is ADRAX, with 658,114,978 options expiring on 15 November 2026 at a $0.005 exercise price. The next largest is ADRAB, comprising 307,204,041 options expiring on 28 February 2028 at $0.02. The ADRAW series, subject to this correction, now totals 325,062,185 options.

Summing all unquoted option series disclosed in Part 4.2, Adherium has over 1.44 billion unquoted options outstanding across thirteen classes, plus 24,656,522 Stock Appreciation Rights (ADRAP). Compared to 53,737,306 quoted ordinary shares (ADR), this represents significant potential dilution if many options are exercised. Investors should note this calculation is based solely on the filing’s figures; actual fully diluted share count depends on exercise outcomes and future capital actions.

Implications of the 31 July 2026 Expiry for ADRAW Options

The ADRAW options expire on 31 July 2026, just one month after this corrective filing, making the timing particularly relevant for holders. Option holders must decide whether to exercise at $0.005 per share before expiry or let the options lapse. The company did not provide guidance on exercise likelihood or current trading context for ADRAW holders.

The immediate market impact of this administrative correction was unclear from public information. However, Market Participants may consider whether formal recognition of these 20 million options adds any overhang risk, especially given the proximity to expiry. Exercised ADRAW options would convert into ordinary ADR shares, increasing the quoted share count beyond 53,737,306.

Issuance Under ASX Listing Rule 7.2 Exception 1

Adherium confirmed in Part 5 of the filing that these securities were issued under ASX Listing Rule 7.2 Exception 1, meaning shareholder approval under Listing Rule 7.1 was not required. This exception applies to securities issued under a prospectus, product disclosure statement, or information memorandum, consistent with the Retail Offer origin of these options.

This procedural detail assures governance-focused investors that the issuance complied with Adherium’s existing shareholder-approved capital framework. No additional shareholder approval was necessary, and the corrective Appendix 3G does not affect the original issue’s legal validity. The options remain in the ADRAW class, ranking equally with other securities from their original issue date of 22 July 2025.

Adherium’s Quoted Shares and Deferred Settlement Securities

The capital table also shows Adherium has 53,737,306 ordinary fully paid shares quoted on ASX (ADR), alongside an equal number—53,737,306—of ordinary fully paid deferred settlement shares (ADRDB). The matching deferred settlement Tranche likely relates to a recent capital raise or restructuring where shares have been issued but not yet settled on a standard basis.

The filing did not elaborate on the deferred settlement shares, their settlement timeline, or the originating transaction. Investors seeking more details on ADRDB securities should consult prior Adherium disclosures. No guidance was provided on when these deferred settlement shares might convert to standard quoted shares.

Overview of Adherium’s Options Expiry Timeline and Upcoming Capital Events

Reviewing all unquoted option series, several expiry dates fall within the next 12 to 30 months, presenting potential capital events. Besides the ADRAW expiry on 31 July 2026, the largest near-term expiry is ADRAX (658,114,978 options at $0.005) on 15 November 2026, which could cause significant dilution if exercised.

Other expiries include ADRAF (525,000 options at $0.01) on 1 April 2027, ADRAG (9,756,250 options at $0.01) on 15 March 2027, ADRAE (400,000 options at $0.008) on 19 June 2027, ADRAH (1,750,000 options at $0.008) on 29 June 2027, and ADRAI (800,000 options at $0.008) on 13 July 2027. Beyond 2027, ADRAB (307,204,041 options at $0.02) expires 28 February 2028, ADRAC (2,000,000 options at $0.0041) expires 9 December 2027, ADRAY (50,000,000 options at $0.02) expires 5 December 2028, and ADRAA (53,908,746 options at $0.01) expires 22 January 2029.

Compliance and Disclosure Responsibilities for ASX-Listed Companies

Filing a corrective Appendix 3G is a standard ASX Listing Rules procedure to rectify incomplete or omitted disclosures of unquoted securities. It does not necessarily signal any substantive change to a company’s operations, strategy, or financial status but highlights the importance of accurate and timely securities reporting to maintain market transparency.

For a company like Adherium, operating in digital health with a complex capital structure spanning multiple option series, precise and current disclosures are vital for investor confidence. The company’s proactive corrective filing—even close to option expiry—demonstrates its commitment to keeping the market informed. Investors and analysts should update their records to reflect the ADRAW class now totals 325,062,185 options outstanding.

Investor Considerations as ADRAW Options Expiry Nears on 31 July 2026

With ADRAW options now formally disclosed and expiring on 31 July 2026, investors should closely watch for any significant exercise activity in the coming weeks. Full exercise of the 325,062,185 options could generate approximately $1.625 million for Adherium at the $0.005 exercise price, although actual proceeds depend on holder decisions.

After ADRAW expiry, attention may shift to the larger ADRAX series expiry on 15 November 2026. Exercise of ADRAX options would have a more substantial impact on Adherium’s share count and capital inflow. The company has not provided forward guidance on capital management or expected exercise activity in this filing, so investors should await future updates for further insights.